- Investing Ideas
- Swedish Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Swedish Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Results
6
Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.
6 companies
AddLife
Market Cap: SEK 19.2b
Provides instruments and equipment, consumables, and reagents primarily to medical care, research, colleges, and universities, as well as the food and pharmaceutical industries.
ALIF B
SEK 157.50
7D
-7.9%
1Y
-15.9%
Bonesupport Holding
Market Cap: SEK 15.8b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
BONEX
SEK 240.00
7D
9.8%
1Y
-19.8%
BioGaia
Market Cap: SEK 12.1b
A healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand.
BIOG B
SEK 119.30
7D
-2.2%
1Y
11.0%
MedCap
Market Cap: SEK 7.6b
A private equity firm specializing in investments in secondary direct, later stage, industry consolidation, add-on acquisitions, growth capital, middle market, mature, turnarounds, and buyout.
MCAP
SEK 508.50
7D
-6.9%
1Y
-2.2%
Genovis AB (publ.)
Market Cap: SEK 1.3b
Develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia.
GENO
SEK 19.00
7D
-8.7%
1Y
-34.5%
Double Bond Pharmaceutical International
Market Cap: SEK 12.9m
A pharmaceutical company, engages in the development and commercialization of approaches for the treatment of oncological and infectious diseases.
DBP B
SEK 0.12
7D
9.1%
1Y
-72.7%